Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. - Wikidata - wikimedia - TriplyDB

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

http://www.wikidata.org/entity/Q34664223

about

Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.Outcomes in relapsed Hodgkin's lymphoma treated with autologous and allogeneic hematopoietic cell transplantation at the Pontificia Universidad Católica de Chile.HIV Testing in Patients With Cancer at the Initiation of Therapy at a Large US Comprehensive Cancer Center.Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study.Very low utility of surveillance imaging in early-stage classic Hodgkin lymphoma treated with a combination of doxorubicin, bleomycin, vinblastine, and dacarbazine and radiation therapy.Comparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy.Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.FDG-PET imaging in hematological malignancies FDG PET/CT imaging as a biomarker in lymphoma.The new therapeutical scenario of Hodgkin lymphoma.XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma.Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging.Novel agents for the treatment of Hodgkin lymphoma.Risk-adapted strategies for the treatment of Hodgkin lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Imaging children suffering from lymphoma: an evaluation of different 18F-FDG PET/MRI protocols compared to whole-body DW-MRI.The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma.Role of bone marrow biopsy in staging of patients with classical Hodgkin's lymphoma undergoing positron emission tomography/computed tomography.Diagnostic yield of EBUS-TBNA for lymphoma and review of the literature.Understanding the information needs of people with haematological cancers. A meta-ethnography of quantitative and qualitative research.Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma-experience at the Lymph Node Registry Kiel.Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Hodgkin Lymphoma Mimicking Osteomyelitis.Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma.No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.The role of FDG-PET in Hodgkin lymphoma Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany.The management of hodgkin lymphomas in pregnancies.Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study.Interim FDG-PET in lymphoma, a questionable practice in hematology.Prognostic value of lymphocyte/monocyte ratio in advanced Hodgkin lymphoma: correlation with International Prognostic Score and tumor associated macrophages.Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.Cardiogenic Shock during First Infusion of Anthracycline Chemotherapy in a Patient with Hodgkin Lymphoma: An Unusual Event.

P2860

Q33578319-F8647DA0-A800-4504-BC92-B595ACB86421 Q33671281-B3EFC9C6-2574-4D40-8A98-967D3F691414 Q35694050-32CF1CBC-3A6D-42A6-ACC4-ACABC18535A3 Q36073717-7EF3B971-8D05-41A4-9303-DCAA2A77B5CE Q36337603-D471C52E-2F5D-4F02-AE0C-288718E66651 Q37149757-163455D7-E6E6-4322-8313-6AC6ECE7CDBA Q37178329-1BA8822E-FF74-4327-832E-C52E16669D5C Q37563122-8800E41A-1C13-4ED1-81E7-25898FB642A8 Q37632114-5D854836-7910-4C53-AA2B-99CAD445212C Q38312367-38E69854-6BB0-40F2-8B0B-FA63E3F2946A Q38513816-C88628DF-C37E-4924-954B-B37966FF68F8 Q38524029-AFCBCCE3-711E-44DE-81AB-5D7933B76327 Q38549745-5ACC5241-DBE6-4AF8-919D-26E34A0553FA Q38581830-FC269B0D-22DC-4D31-8A21-F5CFE39543ED Q38591137-53DFC0F5-BA6E-4A5D-9A91-10508885A64C Q38664909-41C674D0-9BD6-47D4-8544-E0C5051B6294 Q38680358-D5573309-1FB6-45A4-B78F-E787675CC2F0 Q38700459-D858E261-EF58-4EDB-8372-AC3CA5482C0F Q38776129-C92BC1A0-A47C-4328-A367-670C332C734E Q38777496-60E05F4B-0080-4751-9D2E-5F8831BD39CF Q38786377-95232994-64F2-4C90-AAC6-158398CED9A2 Q38792217-D214D341-B492-4F96-8884-6CDD7522D5B3 Q38815516-C08326CD-54ED-4969-BE83-C69E8BCA26A8 Q38819199-4A2B69AE-042F-423A-90CE-C2B30B2C8542 Q39129451-64D96403-57D1-4A35-9C1A-70588E61B5AA Q39132041-5EA7173A-E022-4D38-B554-4C95AA7BC46C Q39324849-38F2CA3E-A44B-40B7-9756-381F671CA29E Q39728290-F62201B7-5CBE-46B9-A52B-877AABAB0E5B Q40040274-DB9FBEDE-D9B1-404D-AB54-2304D91546E8 Q40142429-98CFEBEE-D84B-4C3B-9D10-DFF6371C8B53 Q40588449-EFC1C056-7810-4E85-9241-CD4CE4C84940 Q40929122-079C8311-4ED3-4B36-B002-BE5CCA5AC280 Q41691698-C4F4D851-1411-4857-9913-25845932323A Q47768771-C1E5B879-6D60-4D43-911D-33AB2EED2D24 Q48162570-293BB095-4B15-4B79-8784-FB38577D8700 Q48287544-8A610EE4-7929-4E2A-922D-E82F19C7F357 Q48316502-0AE2F087-AFE0-40A5-938B-FE50346039A0 Q48890938-9959FBAE-1EA3-4F97-A42D-8C8D13B0D472 Q50044569-AF88F43F-1233-47E7-A285-C858FA65934D Q50081496-B5B13BA2-3CC4-422D-9AC1-2299905747C8

P2860

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

http://www.wikidata.org/entity/Q34664223

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@ast

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@en

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@nl

type

label

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@ast

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@en

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@nl

prefLabel

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@ast

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@en

Hodgkin's lymphoma: ESMO Clini ...... osis, treatment and follow-up.

@nl

P1433

Q34664223-8A41D6AD-A398-4513-8879-1C3F65B18F6E

P1476

Q34664223-0E393E6D-AA7F-473B-B00A-3F9F1A2D7545

P2093

Q34664223-48B08898-16A9-46B0-B689-307C36E83F59

Q34664223-540FAEB3-E758-421F-B5D2-55922391B400

Q34664223-9C44BCF5-651D-4D9C-99E5-2B6C32BE496D

Q34664223-AFDED184-E512-4659-B86E-AB8BBD10FE38

Q34664223-B6E77E74-4E93-4940-9BF1-AF668DF8DBEE

P2860

Q34664223-039C9A48-28D2-4143-B567-A3B6DF86D8FE

Q34664223-0ACEC771-234F-4585-BE93-94736428EBA1

Q34664223-10A27B0B-06F3-422C-B279-89F0CA56CD84

Q34664223-12DA4C61-A27B-494E-B8D0-6E724010854C

Q34664223-15A1CE87-6343-40AE-8D2D-1412475B27E8

Q34664223-1784D8C3-35E3-4FD4-8F4B-08BD1C19B557

Q34664223-1DF7133C-304F-4AE3-AF89-4D4195162D82

Q34664223-1E1E62CF-16FD-4B30-B555-3D83546AC264

Q34664223-337CD78F-6186-4C50-8833-47CEB133046B

Q34664223-34F31D4F-0CD8-45DA-BDB3-6681615B9DC6

P304

Q34664223-8570AF51-FAF9-450F-9BBA-591707F5E4A0

P31

Q34664223-29C0FA5E-A4D4-4053-ABC0-E8F229385A87

P356

Q34664223-05D15783-0380-4CC9-B660-3AF3717D5FE7

P478

Q34664223-87DDFFDE-AE84-4960-8C0A-370CC85D5186

P50

Q34664223-2A673BE4-DD1F-4747-AB35-6392DFFB027A

Q34664223-51C66196-2D8C-48CE-92D5-BBB74FF980A5

Q34664223-E64C7674-0592-4D38-AF6C-B30C5AB7026C

P577

Q34664223-70C4C3EA-3131-43CA-9BEB-CD82B9322CDA

P5875

Q34664223-242991B4-8FFF-48D0-9217-0A9FCF0DF5A3

P698

Q34664223-9E49F8EA-E8F8-4B25-B983-4529BD41ED1B

P356

P1433

Annals of Oncology

P1476

Hodgkin's lymphoma: ESMO Clini ...... nosis, treatment and follow-up

@en

P2093

A Engert

http://www.w3.org/2001/XMLSchema#string

D A Eichenauer

http://www.w3.org/2001/XMLSchema#string

ESMO Guidelines Working Group

http://www.w3.org/2001/XMLSchema#string

M André

http://www.w3.org/2001/XMLSchema#string

M Ladetto

http://www.w3.org/2001/XMLSchema#string

P2860

Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly).

Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group.

Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).

P304

iii70-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU181

http://www.w3.org/2001/XMLSchema#string

P478

25 Suppl 3

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Federico

Martin Hutchings

P577

2014-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265342717

http://www.w3.org/2001/XMLSchema#string

P698

25185243

http://www.w3.org/2001/XMLSchema#string